ProMIS Neurosciences Management

Management Kriterienprüfungen 4/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Neil K. Warma

Geschäftsführender

US$40.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	4.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.6yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Neil K. Warma (61 yo)

less than a year

Amtszeit

US$40,000

Vergütung

Mr. Neil K. Warma, MBA, is President, Interim CEO, Principal Executive Officer & Director of ProMIS Neurosciences, Inc. December 30, 2023 and served as its Independent Director since May 13, 2021 until Dec...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Eugene Williams	Co-Founder & Chairman	9yrs	US$275.00k	0.84% $ 244.7k
Neil K. Warma	President	less than a year	US$40.00k	keine Daten
Neil Cashman	Co-Founder	20.1yrs	US$378.82k	0.61% $ 175.8k
Gavin Malenfant	Chief Operating Officer	2.7yrs	US$435.90k	0.014% $ 4.2k
Daniel Geffken	Chief Financial Officer	7.3yrs	US$142.40k	0.031% $ 9.0k
Johanne Kaplan	Chief Development Officer	7.9yrs	US$525.57k	0.025% $ 7.4k
Ernest Bush	Head of Pharmacology/Toxicology & Senior Consultant	6.2yrs	keine Daten	keine Daten
David Wishart	Chief Physics Officer	3.1yrs	keine Daten	keine Daten
Dennis Chen	Head of Manufacturing & Senior Consultant	no data	keine Daten	keine Daten
Larry Altstiel	Chief Medical Officer	2.2yrs	keine Daten	keine Daten

4.6yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrenes Management: PMNDas Führungsteam des Unternehmens gilt als erfahren (4.6 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Eugene Williams	Co-Founder & Chairman	9yrs	US$275.00k	0.84% $ 244.7k
Neil K. Warma	President	3.1yrs	US$40.00k	keine Daten
Neil Cashman	Co-Founder	17.4yrs	US$378.82k	0.61% $ 175.8k
Timothy Rothwell	Member of Business Advisory Board	5.3yrs	keine Daten	keine Daten
William Wyman	Independent Director	10.3yrs	US$40.00k	0.33% $ 96.3k
Nigel Burns	Member of Business Advisory Board	no data	keine Daten	keine Daten
Michael Higgins	Member of Business Advisory Board	no data	keine Daten	keine Daten
William Mobley	Member of Scientific Advisory Board	7yrs	keine Daten	keine Daten
Charles Olanow	Member of Scientific Advisory Board	5yrs	keine Daten	keine Daten
Patrick Kirwin	Independent Director	9yrs	US$40.00k	0.47% $ 136.3k
Sharon Cohen	Member of Scientific Advisory Board	6.3yrs	keine Daten	keine Daten
Madge Shafmaster	Lead Independent Director	2.8yrs	US$40.00k	0% $ 0

6.6yrs

Durchschnittliche Betriebszugehörigkeit

66yo

Durchschnittliches Alter

Erfahrener Vorstand: PMNDie Vorstandsmitglieder gelten als erfahren (6.6 Jahre durchschnittliche Amtszeit).

ProMIS Neurosciences Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

Recent updates

ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter